Current options of ivosidenib in acute myeloid leukemia

Czech version

Authors: M. Čerňan; T. Szotkowski
Authors‘ workplace: Hemato-onkologická klinika LF UP a FN Olomouc
Published in: Transfuze Hematol. dnes,30, 2024, No. 1, p. 7-12.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz1

Overview

Acute myeloid leukemia is the most common type of acute leukemia in adults. The long-term treatment results remain unsatisfactory for the majority of patients. Ongoing research into the process of malignant transformation of the hematopoietic stem cells has revealed new mutations that represent attractive targets for modern drugs. Ivosidenib, an inhibitor of mutated isocitrate dehydrogenase 1 (IDH1), has shown encouraging results in combination with azacitidine in patients with previously untreated acute myeloid leukemia with an IDH1 mutation. The review discusses the current possibilities of using ivosidenib in patients with acute myeloid leukemia in the Czech Republic.

Keywords:

Acute myeloid leukemia – ivosidenib – azacitidine – isocitrate dehydrogenase – IDH1

Sources

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015; 373 (12): 1136–1152.

2. Tian W, Zhang W, Wang Y, et al. Recent advances of IDH1 mutant inhibitor in cancer therapy. Front Pharmacol. 2022; 13: 982424.

3. Fathi AT, Wander SA, Faramand R, Emadi A. Biochemical, epigenetic, and metabolic approaches to target IDH mutations in acute myeloid leukemia. Semin Hematol. 2015; 52 (3): 165–171.

4. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28 (14): 2348–2355.

5. Feng JH, Guo XP, Chen YY, et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis. Am J Blood Res. 2012; 2 (4): 254–264.

6. Zhou KG, Jiang LJ, Shang Z, Wang J, Huang L, Zhou JF. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis. Leuk Lymphoma. 2012; 53 (12): 2423–2429.

7. Döhner H, Wei AH, Appelbaum FR, et al. Diag- nosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140 (12): 1345–1377.

8. Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020; 135 (7): 463–471.

9. Yen K, Chopra VS, Tobin E, et al. Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model. Cancer Res. 2018; 78 (Suppl): abstr. 4956.

10. DiNardo CD, Stein AS, Stein EM, et al. Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diag- nosed acute myeloid leukemia. J Clin Oncol. 2021; 39 (1): 57–65.

11. Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022; 386 (16): 1519–1531.

12. Döhner H, Montesinos P, Vives Polo S, et al. Updated survival, blood count and safety recovery and safety results from the AGILE study in patients with acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. Hemasphere. 2023; 7 (Suppl): e83152da.

13. De Botton S, Montesinos P, Vives Polo S, et al. Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine. J Clin Oncol. 2023; 41: (16 Suppl): 7012.

14. SÚKL: Tibsovo – Souhrn údajů o přípravku [cit. 29. 11. 2023]. Dostupný na: https: //www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_cs.pdf.

15. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015; 126 (3): 291–299.

16. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012; 30 (21): 2670–2677.

17. Heiblig M, Elhamri M, Tigaud I, et al. Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience. Mediterr J Hematol Infect Dis. 2016; 8 (1): e2016009.

18. Duchmann M, Micol JB, Duployez N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study. Blood. 2021; 137 (20): 2827–2837.

19. Pollyea DA, DiNardo CD, Arellano ML, et al. Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations. Clin Cancer Res. 2022; 28 (13): 2753–2761.

20. Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020; 10: 107.

21. Lachowiez CA, Loghavi S, Zeng Z, et al. A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023; 4 (4): 276–293.

22. Short NJ, Zhou S, Fu C, et al. Association of measurable residual disease with survival out-comes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020; 6 (12): 1890–1899.

23. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018; 378 (25): 2386–2398.

24. NCCN Guidelines: Acute myeloid leukemia version 6.2023. [cit. 29. 11. 2023]. Dostupný na: https: //www.nccn.org/professionals/physician_gls/pdf/aml.pdf.

25. Bewersdorf JP, Shallis RM, Derkach A, et al. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leuk Lymphoma. 2023; 64 (1): 188–196.

26. Bewersdorf JP, Shallis RM, Derkach A, et al. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022; 122: 106942.

PODÍL AUTORŮ NA RUKOPISU

MČ – hlavní autor, sepsání první a finální verze manuskriptu
TS – spoluautor, kritická revize rukopisu

PROHLÁŠENÍ

Autor MČ deklaruje konzultační činnost pro společnost Servier, konzultační činnost a cestovní granty od společnosti AbbVie. Autor TS nedeklaruje konflikt zájmů.

DEDIKACE

Práce byla podpořena MZ ČR – RVO (FNOL, 00098892) a IGA_LF_UP_2023_005.

Do redakce doručeno dne: 16. 12. 2023.
Přijato po recenzi dne: 29. 1. 2024.

MUDr. Martin Čerňan, Ph.D.
Hemato-onkologická klinika
LF UP a FN Olomouc
Zdravotníků 248/7
77 900 Olomouc
e-mail: martin.cernan@fnol.cz